Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025
Summary
This bill expands Medicare coverage for cardiac and pulmonary rehabilitation, allowing physician assistants, nurse practitioners, and clinical nurse specialists to administer these services. This directly increases the addressable market for rehabilitation providers and medical staffing agencies. The change is effective immediately upon enactment.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Medicare coverage for cardiac and pulmonary rehabilitation expands to include physician assistants, nurse practitioners, and clinical nurse specialists.
- 2.The addressable market for rehabilitation services and medical staffing agencies increases immediately upon enactment.
- 3.Healthcare providers and medical staffing agencies are direct financial beneficiaries.
Market Implications
This bill creates a bullish environment for healthcare providers and medical staffing agencies. Companies like HCA Healthcare ($HCA) and Universal Health Services ($UHS) will see increased revenue potential from their rehabilitation services. Medical staffing firms such as AMN Healthcare Services ($AMN) and Robert Half International ($RHI) will experience higher demand for qualified personnel, driving their staffing revenues.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Medical Nutrition Therapy Act of 2026
Veterans Community Care Scheduling Improvement Act
Improving Access to Care for Rural Veterans Act
To amend title VII of the Public Health Service Act to strengthen the mental health workforce, and for other purposes.
Access to Genetic Counselor Services Act of 2026
To amend title XVIII of the Social Security Act to establish a full risk ACO program.
Expanded Telehealth Access Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.